New drug combo aims to tame blood cancer without chemo
NCT ID NCT01446133
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants take lenalidomide daily and receive rituximab infusions over several cycles, with response checked after 3, 6, and 12 cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide and rituximab
What this could lead to
If this works, it could offer a chemotherapy-free option to control CLL/SLL, potentially reducing tumor growth and improving response rates.
What could go wrong
This is a mid-stage trial with 120 participants, so results may not apply to everyone. Side effects from the drug combination could occur, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States